A phase 2 study of irinotecan and cetuximab on an every 2 week schedule, as second line therapy in patients with advanced colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 May 2011 Planned End Date changed from 1 Jul 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 03 Oct 2008 Status changed from recruiting to active, no longer recruiting.